## ADUS: Addus HomeCare Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.08 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($110.57)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Loomis Sayles & Co. L P Purchases 20,479 Shares of Addus HomeCare Corporation $ADUS**
- Source: MarketBeat | 20251203T045347 | Somewhat-Bullish | Relevance: 100%
- Loomis Sayles & Co. L P has increased its stake in Addus HomeCare Corporation (NASDAQ:ADUS) by 25.2%, acquiring an additional 20,479 shares to hold a total of 101,705 shares valued at approximately $11.7 million. This move is part of broader institutional investor activity, with institutional investors and hedge funds owning 95.35% of the company. Despite an EVP selling a significant portion of their shares, analysts maintain a "Moderate Buy" rating for Addus HomeCare with a consensus target price of $137.11, following strong quarterly earnings that surpassed estimates.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | BMO Capital | $120 | $0 | 0% |
| 2025-11-07 | RBC Capital | $139 | $134 | +4% |
| 2025-11-05 | TD Cowen | $140 | $139 | +1% |
| 2025-11-04 | Barclays | $117 | $111 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | BMO Capital | init | Market Perform |
| 2025-11-07 | RBC Capital | main | Outperform |
| 2025-11-05 | TD Cowen | main | Buy |
| 2025-11-04 | Barclays | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.03M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Blackrock Inc.: 14.8% (-1.1%)
- Vanguard Group Inc: 7.0% (+2.9%)
- Capital Research Glo: 6.5% (+9.0%)
- Wasatch Advisors LP: 5.1% (+0.8%)
- Silvercrest Asset Ma: 4.6% (+14.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +3%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.08 suggests fair value with growth premium. Balance sheet: low leverage (D/E 0.36). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.0B |
| Beta | 0.94 |
| 52W Range | $88.96 - $136.72 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.08 |
| Forward P/E | 17.2 |
| Current P/E | 19.1 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.5% to 1.0% (-4.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.0pp (needs >4.0% for momentum thesis). MRS_5 (-2.2%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.94), confirming momentum. RSI neutral at 54. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.00% (CS: 61) | Neutral |
| RSI_14 | 54.0 | Neutral |
| MACD Histogram | 0.94 | Bullish |
| vs SMA20 | 1.029x | Above |
| vs SMA50 | 1.016x | Above |
| vs SMA200 | 1.077x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $117.89
- **Stop Loss:** $110.57 (6.2% risk)
- **Target:** $132.53 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 129
- **Position Value:** $15,207.81
- **Portfolio %:** 15.21%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-23 (Est: $1.72)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.53 | $1.56 | +1.7% |
| 2025Q2 | $1.46 | $1.49 | +1.8% |
| 2025Q1 | $1.33 | $1.42 | +6.5% |
| 2024Q4 | $1.36 | $1.38 | +1.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*